OSE Immunotherapeutics Unveils Promising Clinical Findings
OSE Immunotherapeutics SA, a trailblazer in developing innovative therapies for immuno-oncology and immuno-inflammation, is set to present significant new data regarding Lusvertikimab at the prestigious Digestive Disease Week (DDW) 2025 conference. The highlights of this presentation are drawn from a pivotal 24-week Open Label Extension (OLE) period of the Phase 2 clinical trial focusing on ulcerative colitis and will take place in San Diego.
Key Insights on Lusvertikimab and Ulcerative Colitis
Lusvertikimab, an anti-IL-7 receptor monoclonal antibody, has shown a strong safety and efficacy profile during its initial trial phases. This upcoming oral presentation aims to share newly obtained clinical insights from the OLE study, where patients with moderate to severe ulcerative colitis underwent further evaluation from Week 10 to Week 34. The goal is to provide an in-depth understanding of Lusvertikimab's long-term benefits, which is essential for advancing treatment options for chronic autoimmune conditions.
Details of the Presentation
The oral presentation titled "LUSVERTIKIMAB, A FIRST IN CLASS IL7 RECEPTOR ANTAGONIST, IN MODERATE TO SEVERE ULCERATIVE COLITIS: RESULTS OF A MULTICCENTER RANDOMIZED PLACEBO-CONTROLLED PHASE II STUDY" is scheduled for May 5, 2025, at 4:45 PM Pacific Time. It will be featured in the session focusing on Clinical Trials in Inflammatory Bowel Disease (IBD), specifically addressing biologics and emerging therapies.
The Challenge of Ulcerative Colitis
Ulcerative colitis (UC) remains a persistent challenge in gastrointestinal health, characterized by inflammation and ulceration in the gastrointestinal tract caused by an overactive immune system. Currently, UC affects millions of individuals across major global regions, including the US, Europe, and Japan. Despite available treatment options, the remission rates are disappointingly low, with many patients experiencing limited benefits and some resorting to surgery as a final solution.
OSE Immunotherapeutics: A Commitment to Innovation
At OSE Immunotherapeutics, the focus is on creating first-in-class therapeutics. The company partners with leading academic institutions and biopharmaceutical companies, striving to address urgent patient needs through groundbreaking medical advancements. With bases in both Nantes and Paris, the company's commitment to pioneering treatments continues to shape the landscape of therapeutic options available to patients facing severe health challenges.
Upcoming Developments and Future Directions
The data presented at DDW 2025 is expected to bolster the case for continuing the development of Lusvertikimab, not only for ulcerative colitis but also for other chronic autoimmune diseases. Insights derived from the clinical trial findings will be critical for refining treatment strategies and improving patient outcomes.
Contact Information for OSE Immunotherapeutics
For further information about OSE Immunotherapeutics and its innovative developments, stakeholders can reach out to:
Fiona Olivier
fiona.olivier@ose-immuno.com
Sylvie Détry
sylvie.detry@ose-immuno.com
French Media Contact:
Florence Portejoie, FP2COM
fportejoie@fp2com.fr
+33 6 07 768 283
U.S. Media Contact:
Kate Barrette, Rooney Partners LLC
kbarrette@rooneypartners.com
+1 212 223 0561
Frequently Asked Questions
What is Lusvertikimab?
Lusvertikimab is an innovative monoclonal antibody targeting the IL-7 receptor, developed by OSE Immunotherapeutics for the treatment of ulcerative colitis.
When will OSE be presenting the new findings?
The new findings on Lusvertikimab will be presented on May 5, 2025, at the Digestive Disease Week conference.
What are the key benefits of Lusvertikimab?
Initial findings suggest that Lusvertikimab may offer long-term benefits and safety for patients suffering from moderate to severe ulcerative colitis.
How prevalent is ulcerative colitis globally?
UC affects approximately 3.3 million patients across major regions, including the US, Europe, and Japan.
How does OSE Immunotherapeutics contribute to the biotech field?
OSE Immunotherapeutics is committed to developing first-in-class therapies and collaborates with leading institutions to address unmet medical needs in immuno-oncology and immuno-inflammation.
